3 results
The main objective of Study M15-722 is to characterize the efficacy, safety, and tolerability of ravagalimab (ABBV-323) as induction treatment in subjects with moderately to severely active UC.
To evaluate whether the efficacy in terms of progression free survival (PFS) of second-line tepotinib in combination with gefitinib is superior to pemetrexed+cisplatin/carboplatin in subjects with T790M negative, MET+ locally advanced or metastatic…
The main objective is the %TBWL 5 years after surgery. Secondary objectives include Percentage Excess Weight Loss (%EWL); decrease of comorbidities such as diabetes mellitus (DM), hypertension, and hypercholesterolemia; improvement of quality of…